… Erlotinib (Tarceva™; OSI Pharmaceuticals, Genentech and Roche), a quinazoline derivative
… kinases that has been studied in clinical trials. In a Phase I study, mild diarrhoea and mild …

… Similarly, results from the phase III BR.21 study indicated that erlotinib conferred a clinical
… erlotinib therapy. There were no unexpected safety findings relating to erlotinib in this study. …

… Erlotinib was well tolerated in this study with the main toxicities … The promising efficacy of
erlotinib monotherapy in this study … Studies investigating the optimal sequence of erlotinib and …

… for advanced non-small-cell lung cancer (NSCLC) is usually … ) tyrosine-kinase inhibitor
erlotinib has proven efficacy and … ; BO18192) study to assess use of erlotinib as maintenance …

… needs to be validated in future studies. … or erlotinib in several studies. However, a lack of
correlation between EGFR mutations and response to erlotinib was observed in this study. A …

… The epidermal growth factor receptor (EGFR) mutation rate is low in lung SCC. The aim of
this study was to evaluate the status of erlotinib treatment and EGFR mutation in lung SCC …

… patients in this study received erlotinib as a fourth-line or subsequent treatment, the results
from this study were similar to those of clinical studies. We deduce that erlotinib is effective …

… and erlotinib. However, little is known about how the efficacy and safety profile of erlotinib …
We have performed a prospective, randomized phase III study comparing erlotinib with …

… The BR.21 study was a phase 3 trial of erlotinib involving patients who had had progression
… lung cancer. Patients were randomly assigned in a 2:1 ratio to receive 150 mg of erlotinib …

… In the erlotinib study in patients with NSCLC and the gefitinib study … Phase II single-agent
studies with erlotinib, gefitinib, or … combination studies with cetuximab, and one Phase III study …